Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Br J Haematol. 2013 Jan 29;161(1):76–86. doi: 10.1111/bjh.12222

Figure 1. Older Hodgkin lymphoma (HL) patient survival.

Figure 1

The (A) failure-free survival (FFS) and (B) overall survival (OS) for all older HL patients. The (C) 3- and 5-year FFS for older patients who received ABVD was 58% and 53%, respectively, which compared with 54% and 42%, respectively, for patients who received Stanford V (p=0.99); while the (D) 3- and 5-year OS for older patients who received ABVD was 73% and 64%, respectively, which compared with 67% and 51%, respectively, for patients who received Stanford V (p=0.90).